Participants in the DT group were treated with a NOAC plus a P2Y12 inhibitor.

Participants in the TT group were treated with aspirin, a P2Y12 inhibitor and a vitamin K antagonist.

Major adverse cardiac events (MACEs)[10] were defined as a combination of all-cause death, myocardial infarction, stroke, and revascularization.

Stent thrombosis was defined according to the Academic Research Consortium (ARC).[11]

International Society on Thrombosis and Hemostasis (ISTH) major bleeding[12] has been defined as clinically overt bleeding that is associated with a fall in hemoglobin of 2 g/dl or more, or a transfusion of 2 or more units of packed red blood cells or whole blood or a critical site such as intraocular, intraspinal, intracerebral, pericardial, intra-articular, retroperitoneal, or a fatal outcome.

Thrombolysis in Myocardial Infarction (TIMI) major bleeding[12] has been defined as any symptomatic intracerebral hemorrhage, or clinically overt signs of hemorrhage including imaging, associated with a decrease in hemoglobin of equal to or more than 5 g/dl or an absolute decrease in hematocrit level of ≥15%.

TIMI minor bleeding[12] has been defined as any clinically overt sign of hemorrhage that is associated with a decrease in hemoglobin level of 3 to 5 g/dl or a fall in hematocrit of 9% to 15%.

The adverse cardiovascular outcomes and bleeding events which were reported in the original studies have been listed in Table Table11 and the outcomes which have been analyzed included:

The outcomes and follow-up which were reported in the original studies.

MACEs;

Myocardial infarction (MI);

Stroke;

Mortality;

Stent thrombosis;

Total major bleeding;

Total minor bleeding;

TIMI defined major bleeding;

TIMI defined minor bleeding;

Intracranial bleeding;

ISTH major bleeding.

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.